The natural R-form of alpha-lipoic acid degrades rapidly when exposed to heat, light, or moisture
Supplementation trials show dose-dependent benefits for type II diabetics
--- Here are some potential actions covered in the article for payers and employers to take as a result of this shift: Update formulary tiers and step therapy policies (consider the impact on comorbidities) Support members transitioning off GLP-1s after reaching their goals Create differentiated access pathways based on patient risk profiles Monitor realworld outcomes beyond A1C (cardiovascular, renal, adherence) Model the downstream impact on generics and legacy therapies --- Commercial plans are accelerating GLP-1 uptake and favoring the simplicity of a single therapy
If you have diabetes, your insurance is much more likely to cover it
Parsad D, Pandhi R, Juneja A
First, GSH levels in rat and human brains were analyzed using proton magnetic resonance spectroscopy (Reliable Source)